Amgen ended all of its clinical studies of rilotumumab in advanced gastric cancer, including the phase III RILOMET-1 and RILOMET-2 trials.
A phase II trial of Imbruvica showed that more than 30 percent of treated relapsed/refractory mantle cell lymphoma patients remained progression-free after two years with no new or unexpected adverse events occurring during that time. Forty-seven percent of the 111 patients treated were still living at the 27-month median follow-up.
Premenopausal women who received ovarian suppression treatment along with tamoxifen had a lower risk of breast cancer recurrence, according to data from a clinical trial sponsored and supported by NCI.
FDA approved Lynparza (olaparib) capsules as monotherapy for the treatment of patients with deleterious or suspected deleterious germline BRCA mutated advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy. FDA also approved a molecular companion diagnostic.
FDA approved Cyramza (ramucirumab) in combination with paclitaxel as a treatment for advanced or metastatic stomach or gastroesophageal junction adenocarcinoma whose cancer has progressed on or after prior fluoropyrimidine- or platinum-containing chemotherapy.
The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month. For further information, contact the principal investigator listed.
Updated interim results from the ongoing ARMOR2 phase II clinical trial of galeterone in castration-resistant prostate cancer patients demonstrated the potential of galeterone to treat CRPC expressing androgen receptor splice variants, including AR-V7, according to researchers.
Positive results from an ongoing phase II study of BIND-014 in non-small cell lung cancer showed that it has met the primary objective in the once-every-three-weeks arm, as measured by overall response rate. The data demonstrate that BIND-014 is well-tolerated with clinically meaningful anti-tumor activity at a lower dose than conventional docetaxel in patients with advanced or metastatic NSCLC.
A phase III trial of Tumor Treating Fields was terminated early following early success detailed in an interim analysis. The trial evaluated patients with newly diagnosed glioblastoma being treated with the NovoTTF-100A System, developed by Novocure, in combination with standard-of-care temozolomide.
Top-line secondary endpoint results from the phase III TRINOVA-1 trial in women with recurrent platinum-resistant ovarian cancer did not demonstrate a statistically significant improvement in overall survival. The study evaluated trebananib plus paclitaxel versus placebo plus paclitaxel.
